Engineered immune cells take aim at Hard-to-Treat blood cancers

This study tested whether a new type of immune cell therapy, called CD22 CAR T cells, could be made from the blood of adults with certain blood cancers (leukemia and lymphoma) that had come back or not responded to treatment. The main goals were to see if the cells could be successfully produced and to check for safety. The approach involved collecting patients' own immune cells, modifying them to target cancer, and infusing them back after chemotherapy.